Fuwai Central China Cardiovascular Hospital
Zhengzhou, 450003, China
Location status: Recruiting
NCT Number: NCT06620458
The purpose of this study is to analyze potential factors post paclitaxel drug-coated balloon angioplasty in patients with Denovo large vessels disease. It includes imaging endpoints and clinical event endpoints. Over 5000 patients are expected to be enrolled.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Zhengzhou, 450003, China
Location status: Recruiting
This study is a retrospective analysis that retrospectively reviewed over approximately 5000 patients with de novo-large-vessel disease who underwent paclitaxel drug-coated balloon angioplasty. The study endpoints include cardiovascular adverse events at 1 year (cardiovascular death, cardiovascular events) and coronary angiographic outcomes (primarily late lumen loss, restenosis rate). It primarily focuses on differences in baseline characteristics, lesion features, intracavitary imaging characteristics(Including OCT, IVUS), hemodynamic parameter,and procedural approaches among patients. Over 5000 patients are expected to be enrolled.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
18 years and older.
Diagnosed with coronary artery disease with native large vessel lesions confirmed by coronary angiography.
Scheduled to receive paclitaxel drug-coated balloon angioplasty.
Patients have been fully informed about the nature and purpose of the study, and have voluntarily agreed to participate, with signed informed consent.
Cardiac function classified as NYHA I-III.
Exclusion criteria
Known allergies to paclitaxel or any materials used in angioplasty (e.g., contrast agents).
Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg).
Active bleeding or clotting disorders.
Time frame: 12 months
cardiovascular adverse events:defined as death, Myocardial Infarction (MI, Q waves and non-Q waves), emergent cardiac bypass surgery, or any target lesion revascularization (repeat Percutaneous transluminal coronary angioplasty (PTCA) or Coronary artery bypass grafting (CABG)).
Time frame: 12 months
Detection by QCA technique by subtracting the minimum lumen diameter at review from the minimum lumen diameter in the immediate postoperative period
Contact information is provided by the study sponsor or research team.
Henan Institute of Cardiovascular Epidemiology
Other
Acronym: RE-DCB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07720349
Arterial Occlusive Diseases, Arteriosclerosis
Arendal, Norway
View Trial DetailsNCT02038127
Arterial Occlusive Diseases, Arteriosclerosis
Chuncheon, Gangwon-do, South Korea
View Trial DetailsNCT07190690
Arterial Occlusive Diseases, Arteriosclerosis
Alicante, Spain
View Trial DetailsNCT05611307
ASCVD, Arterial Occlusive Diseases
Indianapolis, Indiana, United States
View Trial Details